Artsyl Technologies Recognized as Top Performer in Accounts Payable Automation Software
Delivering Cutting-Edge Automation Solutions with Proven Customer Success
'This recognition as a Top Performer in Accounts Payable Automation Software highlights our dedication to helping businesses simplify AP workflows with our AI-powered IPA solution - docAlpha.' — Artur Vassylyev, President / Dir. of Engineering at Artsyl Technologies
VAUGHAN, ON, CANADA, January 28, 2025 / EINPresswire.com / -- Artsyl Technologies, Inc., a leading provider of Intelligent Process Automation (IPA) solutions, is proud to announce its recognition as a Top Performer in the FeaturedCustomers Winter 2025 Accounts Payable Automation Software Customer Success Report. This designation highlights Artsyl's exceptional impact in transforming accounts payable processes for businesses worldwide.
The FeaturedCustomers report, which evaluates over 7,000 pieces of verified customer reference content, honors the industry's best by analyzing real-world success stories and customer satisfaction. As a Top Performer, Artsyl stands out for its innovation, reliability, and commitment to delivering measurable results for its clients.
Why Artsyl Was Selected as a Top Performer in Accounts Payable Automation Software Category
Artsyl's docAlpha Intelligent Process Automation platform and vertical solutions for AP automation, such as InvoiceAction, OrderAction, and ArtsylPay, set the benchmark for excellence in accounts payable automation. Designed to address the complexities of AP processes, Artsyl's solutions empower businesses to achieve unparalleled efficiency and accuracy.
Key benefits of Artsyl's AP automation solutions include:
• AI-Powered Automation: Leverages advanced artificial intelligence to extract, validate, and process invoice and order data with unmatched speed and accuracy.
• Cloud-Based Infrastructure: Offers secure, scalable, and remote-accessible automation, hosted on Microsoft Azure, providing flexibility for businesses of all sizes.
• SOC 2 Certified: Demonstrates Artsyl's commitment to the highest standards of data security, confidentiality, and compliance, ensuring peace of mind for customers in regulated industries.
• Tight ERP Integration: Seamlessly integrates with leading ERP systems, including SAP, NetSuite, MS Dynamics, Sage, Acumatica, IFS, and others, creating a streamlined, end-to-end AP workflow.
• ArtsylPay for Payment Automation: Enables secure and efficient payment processing while offering rebate opportunities, further enhancing ROI.
• Vendor Onboarding and Compliance: Automates the onboarding process, ensuring all vendor data is validated and compliant with regulatory standards.
• Real-Time Insights: Provides actionable insights through intuitive dashboards and analytics, allowing businesses to monitor and optimize AP workflows.
• Error Reduction and Cost Savings: Minimizes manual errors, reduces processing costs, and accelerates approval cycles to boost overall productivity.
Artsyl's innovative solutions not only simplify AP processes but also enable businesses to unlock the full potential of automation. These features and benefits solidify Artsyl's well-deserved recognition as a Top Performer in Accounts Payable Automation Software.
What This Means for Artsyl's Customers
Being recognized as a Top Performer reaffirms Artsyl's dedication to delivering world-class AI-based automation solutions, particularly for accounts payable processes. At the heart of this recognition is Artsyl's flagship docAlpha Intelligent Process Automation platform, hosted on Microsoft Azure, which provides robust security, seamless ERP integration, and unmatched scalability.
docAlpha and its vertical solutions, including InvoiceAction, OrderAction, and ArtsylPay, empower businesses to streamline AP workflows by automating document processing, invoice management, order processing, and payment management. These tools drive measurable benefits such as reduced errors, faster approval cycles, and significant cost savings.
'This recognition as a Top Performer in Accounts Payable Automation Software underscores our commitment to helping businesses simplify their AP workflows,' said Artur Vassylyev, President / Dir. of Engineering at Artsyl Technologies. 'With IPA platform like docAlpha, we enable our customers to eliminate inefficiencies, meet compliance requirements, and enhance productivity—all while leveraging the power of intelligent automation.'
By continuing to innovate and prioritize customer success, Artsyl remains a trusted partner for businesses seeking secure, scalable, and effective automation solutions in the ever-evolving AP landscape.
Looking Ahead: Innovation and Growth
As a Top Performer in Accounts Payable Automation Software, Artsyl is dedicated to continuously enhancing its product suite to meet the evolving demands of its customers. This recognition underscores Artsyl's unwavering commitment to innovation, enabling businesses to achieve greater efficiency, accuracy, and competitive advantage in a rapidly evolving marketplace. Discover how Artsyl's award-winning solutions can transform your AP processes. Contact us today https://www.artsyltech.com/ to explore your automation journey!
About FeaturedCustomers
FeaturedCustomers is a trusted platform that showcases B2B business software and services through verified customer success content. Its Winter 2025 Accounts Payable Automation Software Customer Success Report reflects an in-depth analysis of real-world customer experiences, ensuring unbiased recognition of the industry's leading software providers. To learn more about FeaturedCustomers, please visit https://www.featuredcustomers.com/
About Artsyl Technologies, Inc.
Artsyl Technologies, a leading publisher of Intelligent Process Automation (IPA) platforms, is dedicated to eliminating the inefficiencies of manual and error-prone processes. By harnessing the power of Digital Transformation technologies such as Robotic Process Automation, Cognitive AI, Machine Learning, IDC, OCR/ICR, BPM, and iPaaS, Artsyl's solutions drive operational efficiency, improve cash management, and accelerate business velocity.
At the core of Artsyl's offerings is their Intelligent Process Automation platform, which streamlines and automates complex business processes. Through this platform, Artsyl also provides pre-packaged Action Solutions tailored to specific processes like Invoice and Sales Order automation. These pre-configured solutions deliver process-specific intelligence, enabling efficient and cost-effective implementations.
ArtsylPay, their cutting-edge payment automation solution, seamlessly integrates with the Intelligent Process Automation platform. By automating payment processing, ArtsylPay enhances cash management and drives operational savings for businesses.
To learn more about Artsyl Technologies and their innovative solutions, please visit https://www.artsyltech.com. Experience the future of process automation and payment solutions with Artsyl.
Vita Vasylyeva
X
LinkedIn
YouTube
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Turkish apparel sector to gain edge with İHKİB-Bilişim Vadisi pact
The collaboration between İHKİB and Bilişim Vadisi will focus on the development of projects and work packages that will contribute to the Turkish apparel industry, with an emphasis on twin transformation, sustainability, circular economy, and design. Both organisations will seek national and international support programmes that concentrate on digitalisation, green transformation, sustainability, circular economy, and creative industries. The partners intend to create projects and work packages that align with strategic goals within technology and design sectors, forming solution-oriented partnerships with affiliates and stakeholders in the areas of digital transformation and design processes. Additionally, they plan to collaborate through initiatives such as digitalisation and design clustering centres. Entrepreneurs from Bilişim Vadisi will have the opportunity to expand their businesses through partnerships with members of İHKİB. Bilişim Vadisi general manager Erkam Tüzgen said: 'Next-generation textile technologies are being driven not only by major players but also by creative start-ups. Through this programme, we are bringing together young entrepreneurs, designers, and technology developers within a shared ecosystem. Bilişim Vadisi will continue to act as a catalyst at this intersection of technology and design.' Speaking at the signing ceremony, İHKİB vice president Mustafa Paşahan highlighted Türkiye's role as one of the largest apparel suppliers globally, accounting for 3.2% of worldwide apparel exports. Paşahan said: 'We already comply with European standards in areas such as recycling, carbon footprint reduction, digitalisation, and social compliance. To further strengthen our position in global markets, we aim to build on these existing strengths and turn digital and green transformation into key opportunities. In this process, we are making effective use of EU funds through projects developed under the IPA (Instrument for Pre-accession Assistance). So far, we have secured €37m ($42.25m) in EU funding.' İHKİB will use EU's funding to initiate a 'Carbon Footprint Tracking and Reduction' project later in the year. 'With our new partnership with Bilişim Vadisi, we believe we will launch many innovative projects that will further enhance the global competitiveness of our fashion industry, especially in digitalisation and green transformation,' Paşahan added. In February this year, İHKİB completed METAMORPHOSIS project under IPA II, which led to the creation of a Digital Transformation Center for the industry. The association also launched the MIDAS project, with support from the EU, to provide infrastructure for twin transformation among SMEs. "Turkish apparel sector to gain edge with İHKİB-Bilişim Vadisi pact" was originally created and published by Just Style, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Associated Press
3 days ago
- Associated Press
Capital Vacations Reviews The Social Benefits of Vacation Ownership
Building Community Through Travel 'Our social events, engaging activities, and welcoming resort atmosphere help owners build memories that last a lifetime,'— Travis Bary, Co-President of Capital Vacations MYRTLE BEACH, SC, SC, UNITED STATES, June 6, 2025 / / -- Vacation ownership offers more than just a place to stay—it creates meaningful connections and a strong sense of community among owners. Travel brings people together, and vacation ownership provides a unique opportunity for families, friends, and fellow travelers to build lasting relationships. Whether returning to a favorite destination, joining owner events, or sharing stories by the pool, the social side of ownership transforms vacations into cherished memories. Engaging in social events and creating long-standing friendships during vacations goes beyond just entertainment — it significantly supports mental and emotional well-being. Group activities and shared experiences allow individuals to relax, recharge, and form deeper bonds, often creating a support network that extends beyond the resort stay. Capital Vacations, through its points-based ownership club, hosts a variety of social events designed to bring owners together and enrich the vacation experience. These include experiences like: • Vegas-Style Game Nights: High-energy evenings with food, an open bar, DJs, and table games like roulette, poker, and blackjack—complete with prizes for the winners. • Themed Parties and Dinners: Events such as Hawaiian luaus and live concerts encourage interaction and leave lasting impressions. • Live Entertainment: Performances by talented artists create shared moments and lasting memories. Through these activities, guests can meet new people, share meaningful experiences, and form friendships that keep them actively vacationing and exploring. This sense of connection enhances every visit and deepens the value of ownership. 'At Capital Vacations, we believe travel is about more than getting away—it's about creating lasting experiences and genuine connections. Our social events, engaging activities, and welcoming resort atmosphere help owners build memories that last a lifetime,' says Travis Bary, Co-President of Capital Vacations To learn more about Capital Vacations Club and its expanding portfolio of premier vacation destinations, visit # # # About Capital Vacations Capital Vacations is reimagining the travel experience by connecting Independent Resorts with travelers through our technology platform and vacation products. We partner with more than 200 Independent Resorts across the U.S. and Caribbean, deploying strategic value-add tools that allow Independent Resorts to increase revenues across multiple channels. In addition, we service over 1,000,000 travelers a year with a hyper-focus on the owner and guest experience and the creation of long-term relationships. Visit Travel. Gather. Smile. Repeat. Andy Kovan Capital Vacations +1 843-251-6415 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Business Wire
4 days ago
- Business Wire
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENS ai ™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the Company's newly launched, HYFT pattern-patented AI-native vaccine discovery engine. Unlike traditional trial-and-error methods, IPA's discovery was achieved entirely in silico, demonstrating the platform's power to translate complex biological data into actionable vaccine design. Share Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO commented, 'This breakthrough highlights a new frontier in AI-driven biology—where discovery is rooted in the biology of a virus itself. By confirming that our sequence-derived patented HYFT patterns match structural signatures across all dengue serotypes, we're setting the stage for a universal vaccine design framework. Ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. More importantly, the implications appear to stretch far beyond the dengue virus. This is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.' Building on this success in dengue, IPA now intends to extend its AI-driven vaccine design platform to other high-impact infectious diseases, for example, HIV, Norovirus, and an improved RSV vaccine. Early-stage assessments are also underway to explore the platform's application in oncology for neoantigen vaccine development and tumor-specific epitope mapping. This discovery underscores IPA's commitment to advancing drug discovery through innovative, human-relevant AI technologies that align with evolving industry standards. Using HYFT's patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the Company's proprietary LENS ai platform identified a unique epitope shared across all four serotypes of the dengue virus—DENV-1, DENV-2, DENV-3, and DENV-4. These serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. Unlike traditional trial-and-error methods, IPA's discovery was achieved entirely in silico, demonstrating the platform's power to translate complex biological data into actionable vaccine design. Breaking the Dengue Barrier: Patented HYFT-Powered AI Achieves What Decades of Science Could Not Why Has a Universal Dengue Vaccine Been So Elusive? Dengue is not just one virus—it's four distinct, rapidly-evolving serotypes. Immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. For decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus's rapid mutation and complex immune interactions. Traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale. Confirmed Breakthrough: Sequence and Structural HYFT Match Across All Four Serotypes IPA's discovery is a landmark moment in computational vaccinology. Using its proprietary LENSai™ platform powered by their patented HYFT® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes— a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. This achievement marks a critical milestone in the quest for a universal dengue vaccine. What sets this apart is the depth of validation: Patented HYFT patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural HYFTs across all four dengue serotypes. This was made possible through LENS ai 's integration of over 20 million proprietary Structural HYFTs (S-HYFTs), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints. The validation demonstrates that LENS ai doesn't simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-EM. This milestone affirms the patented HYFT technology's unique ability to traverse the full biological hierarchy—from DNA/RNA sequence to molecular structure to therapeutic relevance. It signals that AI-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research. The end-to-end LENS ai platform integrates patented HYFT® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. The result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the LENS ai ™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery and vaccine development methods; the expansion of IPA's discovery engine to additional infectious disease and oncology targets; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
